

CROI 2008 Program at-a-Glance

Time	DAY 1	DAY 2	DAY 3	DAY 4	Thursday, February 7
	Sunday February 3	Monday February 4	Tuesday February 5	Wednesday February 6	
8:30-9 am		Plenary Morbidity and Mortality in the HAART Era	Plenary Challenges in Pediatric and Adolescent HIV Care	Plenary Advances in Management of Treatment-Experienced Patients: A 2 nd Wave of HAART	post-conference activities including: debriefing sessions, investigator meetings, working group meetings, affiliated events
9-9:30 am	Program Committee Workshop for New Investigators and Trainees	Plenary Whole Genome Analysis: Cellular Genes Affecting Virus/Host Interplay	Plenary Natural Enhancers and Inhibitors of HIV Infection	Plenary Endogenous Retroviruses: Ancient Pathogens and Host Defense	
9:30-10 am		<i>Break</i>	<i>Break</i>	<i>Break</i>	
10-11 am		Host Genomics Hands-on Computer Workshop	Oral Abstract Sessions Epidemiology of SIV/HIV Infection and AIDS-related Malignancies Viral Pathogenesis and Immune Surveillance Prevention Strategies New Antiretrovirals and Clinical Trials	Oral Abstract Sessions Insights into Neuropathogenesis HIV in Women and Children New Mechanisms of Resistance and Virologic Failure HIV Vaccines	
11 am-12 pm	11:30 am-12:30 pm Luncheon Presentation: History of AIDS (by invitation only)		Plenary The Current State of HIV Vaccine Science		
12-1 pm		<i>Lunch</i>	Plenary The Quest for an AIDS Vaccine: Where Do We Go from Here? <i>Lunch</i>	<i>Lunch</i>	
1-2 pm		Poster	Poster	Poster	
2-3 pm	Opening Symposium Scale-up of HIV Prevention and Treatment in the Developing World	Poster Discussions	Poster Discussions	Poster Discussions	
3-4 pm		Sessions	Sessions	Sessions	
4-6 pm	Opening Plenary & Keynote Session 13th Bernard Fields Lecture Douglas Richman <i>Univ of California, San Diego, US</i> 2nd N'Galy-Mann Lecture Ron Gray, David Serwadda, Nelson Sewankambo, & Maria Wawer, <i>The Rakai Hlth Sci Prgrm</i> Keynote Lecture TBD	Symposia Voyages through the Cell: Imaging Viral Traffic Curbing the US Epidemic Oral Abstract Sessions Prevention of MTCT Hepatitis Co-infection	Symposia The Emerging Science of HIV Prevention in Women Aging and AIDS Targeting TB: New Opportunities and Challenges Oral Abstract Session HIV Molecular Biology and Host Cell Interactions	Symposia Accessory Proteins and their Role in Virus Biology Frontiers in Vaccine Research Individualizing Patient Management	
6-8 pm	Welcome Reception				

CR I 2008 Poster Sessions

Time	Monday, February 4	Tuesday, February 5	Wednesday, February 6
1-4 pm	Poster Sessions		
Hall D	<p>Cellular Co-factors</p> <p>Cellular Restrictions</p> <p>Viral Accessory Genes</p> <p>Factors Impacting Disease Progression</p> <p>Factors Impacting Viral Replication <i>in vivo</i></p> <p>Studies on Viral Evolution <i>in vivo</i></p> <p>Therapy and CNS Infection</p> <p>Emerging Issues in Neuropathogenesis</p> <p>Studies on T Cell Responses in Viral Infection</p> <p>Studies on Cytokines and HIV Infection</p>	<p>New Insights into APOBEC Proteins</p> <p>Viral Replication Cycle: Molecular Studies</p> <p>Viral Envelope: Tropism and Coreceptor Studies</p> <p>Viral Fitness, Evolution and Recombination</p> <p>CTL Studies and Consequences of Immune Escape</p> <p>Factors Influencing CD4 Counts</p> <p>HIV Superinfection and Viral Co-infection</p> <p>Virologic Parameters in NeuroAIDS</p> <p>Studies into Mechanisms of HIV Neuropathogenesis</p> <p>Immune Activation and Lymphocyte Function</p> <p>Studies on Regulatory T Cells</p> <p>Immune Responses and Control of Viremia</p>	<p>HIV-1-Macrophage Studies</p> <p>Co-infection: Virus/Virus Interactions</p> <p>Viral Reservoirs</p> <p>Viral Transmission: Molecular Studies</p> <p>Studies on Elite Controllers and Exposed Uninfected</p> <p>Studies of Non-progressive Infection</p> <p>Lymphocyte Depletion in the Gut</p> <p>Monocyte/Macrophage Studies</p> <p>Co-infection with HCV</p> <p>PML and JC Virus</p> <p>B Cell and Immunoglobulin Studies</p> <p>Studies on NK and Plasmacytoid Dendritic Cells</p> <p>HIV Vaccines: Induction of Neutralizing Antibodies and Responses</p> <p>HIV Vaccines: Induction of Cellular Immune Responses</p> <p>HIV Vaccines: Novel Viral Vectors</p> <p>HIV Vaccines: Clinical Trials</p>
Hall A	<p>Molecular Epidemiology: The Americas</p> <p>Molecular Epidemiology: Europe</p> <p>Molecular Epidemiology: Africa and Asia</p> <p>Epidemiology and Transmission in Adult Populations</p> <p>Novel PrEP Agents and Evaluation Strategies</p> <p>Pharmacokinetics and Children</p> <p>Response to and Efficacy of ART in Children</p> <p>Resistance after First-line Failure in Children</p> <p>Antiretroviral Pharmacokinetics during Pregnancy</p> <p>Resistance Associated with ART for PMTCT</p> <p>Health Outcomes in Women</p> <p>Infertility in HIV-infected Women</p> <p>Acute HIV/SIV/Infection: Characterization of Transmitted Viruses</p> <p>Acute HIV/SIV Infection: Immune Responses</p> <p>Acute HIV Infection: Treatment</p> <p>Acute HIV Infection: Recognition and Correlates of Transmission</p>	<p>New Approaches to HIV Testing</p> <p>HIV-1 Prevention for Positives</p> <p>Modeling the Cost-effectiveness and Impact of PrEP on Resistance</p> <p>Complications, Neurodevelopment and ART-related Toxicities in Children</p> <p>Mycobacterial Disease in Children</p> <p>Prevention, Identification and Treatment of at Risk and HIV Infected Adolescents</p> <p>Prevention of Postnatal MTCT</p> <p>Infant Feeding, PMTCT and Infant Outcome</p> <p>Properties of Breast Milk</p> <p>Influence of Gender on HIV Replication and Viremia</p> <p>HIV Replication, Immune Activation, HIV-2 Co-infection, and Genital Shedding in Women</p> <p>ART: Novel Approaches I</p> <p>ART: Novel Approaches II</p> <p>Clinical Pharmacology of Reverse Transcriptase Inhibitors</p> <p>Clinical Pharmacology of Protease Inhibitors</p>	<p>Expanding HIV Testing</p> <p>Behavioral Risk in HIV Infection</p> <p>Preclinical and Clinical Studies of Topical and Oral PrEP</p> <p>Special Considerations in Laboratory Studies for Children</p> <p>Diagnosing HIV Infection in Infants and Children</p> <p>Immune Response in Children</p> <p>Viral and Host Factors Associated with Pediatric Disease Progression</p> <p>Risk, Timing and Viral Genetics of MTCT</p> <p>Co-infections during Pregnancy</p> <p>Immune-Based Therapies: Cytokines</p> <p>Immune-Based Therapies: Therapeutic Vaccines</p> <p>Immune-Based Therapies: Novel Approaches</p>

CR I 2008 Poster Sessions *(cont)*

Time	Monday, February 4	Tuesday, February 5	Wednesday, February 6
1-4 pm	Poster Sessions		
Hall B	<p>ART: Treatment-naïve Patients</p> <p>ART: Treatment-experienced Patients</p> <p>Treatment Outcomes in Scale-up Programs</p> <p>New Mechanisms of HIV-1 Drug Resistance</p> <p>Viral Rebound and Emergence of Drug Resistance</p> <p>HIV-1 Drug Resistance after First-line Therapy</p> <p>Changing Prevalence of HIV-1 Drug Resistance</p> <p>Impact of Subtype on HIV-1 Drug Resistance</p> <p>Simplified Diagnostics for Resource-limited Settings</p> <p>Evaluation of Serodiagnostic Assays</p> <p>HLA Testing: Refinements and Cost-effectiveness</p> <p>Dyslipidemia: Role of ART and Interventions for Management</p> <p>Lipoatrophy/Lipohypertrophy: Predictors and Interventions</p> <p>Atherosclerosis, Cardiovascular Risk and HIV Infection</p> <p>Hepatitis B Co-infection</p> <p>Hepatitis C Co-infection: Cellular Immune Responses and Pathogenesis</p> <p>Hepatitis C Co-infection: Fibrosis</p>	<p>Switching Therapy and Treatment Failure in Scale-up Programs</p> <p>Resistance to New Antiretrovirals</p> <p>Emerging Patterns of Resistance to New Antiretrovirals</p> <p>Minor Drug-resistant Variants: Detection and Clinical Significance</p> <p>Impact of Subtype on HIV Quantification</p> <p>New Diagnostic and Monitoring Tools</p> <p>Hepatic Complications</p> <p>Markers of Inflammation, Immunodeficiency and Complications</p> <p>Changes in Bone Mineral Density</p> <p>Renal Disease</p> <p>Hepatitis C Co-infection: Markers, Outcome and Effect of ART</p> <p>Hepatitis C Co-infection: Treatment</p> <p>Hepatitis Co-infection: Cardiovascular and Malignancy Association</p>	<p>ART: Adherence</p> <p>HIV Care in Different Settings</p> <p>Risk Factors for Lost-to-Follow-up in Resource-limited Settings</p> <p>Complications in Resource-limited Settings</p> <p>New Resistance Technologies</p> <p>HIV-1 Drug Resistance: Genital Shedding and Recombination</p> <p>HIV-2 Drug Resistance</p> <p>Diagnosis and Monitoring Using Dried Specimens</p> <p>Impact on Cardiac Function</p> <p>Hypersensitivity Reactions: Other Drug Toxicities in vitro and Animal Studies of Metabolic Toxicity</p> <p>ART Toxicity in Resource-limited Settings</p> <p>TB Screening and Diagnostics</p> <p>HIV/TB Co-infection</p> <p>TB-associated Immune Reconstitution Inflammatory Syndrome</p> <p>Cryptococcal and Herpesvirus Infections</p> <p>Infectious Complications</p> <p>Malignancies</p>
2-3 pm	Poster Discussions		
	<p>Lymphocyte Depletion in the Gut</p> <p>Emerging Patterns of Resistance to New Antiretrovirals</p> <p>New Approaches to HIV Testing</p>	<p>Clinical Developments in Neuropathogenesis</p> <p>Risk Factors for Lost-to-Follow-up in Resource-limited Settings</p> <p>Novel PrEP Agents and Evaluation Strategies</p> <p>TB-associated Immune Reconstitution Inflammatory Syndrome</p>	<p>New Insights into APOBEC Proteins</p> <p>Prevention of Postnatal MTCT</p> <p>Molecular Epidemiology: The Americas</p>